An observational study in Chronic Obstructive Pulmonary Disease, Cardiovascular Diseases and Lung Cancer, sponsored by Region Skane. Enrolling by invitation at 1 site in Sweden. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Region Skane · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden — 16 open to participants now, 24 under way, 6 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sweden.
Among the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden, this one is the 6th largest by planned enrollment of the 28 observational ones that give a count, is one of 8 that started in 2013, is one of 29 observational ones, reaches primary completion later than 8 of the 23 other live ones, and was the 49th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →16 of the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in Sweden, United States, Denmark and 6 more countries
Ages 18–80
Björn Nordlund · Sites in Sweden
Ages 40+
Sanofi · Sites in Sweden, United States, Argentina and 19 more countries
Ages 40–85
Sanofi · Sites in Sweden, United States, Argentina and 22 more countries
Ages 40–80
GlaxoSmithKline · Sites in Sweden, United States, Argentina and 20 more countries
Ages 40–80
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 45 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 24 · Phase 3 44 · Phase 4 15
First in 1987; this study’s year is marked. 8 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 229 across the 123 interventional studies, 470 across the 28 observational. Of the 124 that completed or were terminated, 56 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 152 have an industry lead sponsor. The 10 most frequent:
Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.
Region Skane has 2 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
6 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT01460264Region SkaneAn Open Prospective Longitudinal Pulmonary-cardiovascular Cohort Study | 2026-12 |
| NCT05008081Wim JanssensThe CATALINA Study | 2027-03 |
| NCT07573098Björn NordlundDigital Tool for Improved Self-management of COPD | 2027-05-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational study aiming to identify and validate biomarkers (including imaging and clinical descriptors) for chronic obstructive pulmonary disease (COPD), cardiovascular disease (CVD) and lung cancer.
Community sample,residents in Skåne county Sweden.
Inclusion Criteria:
current daily smokers 100 cigarettes or more during lifetime
current non-smokers
Started Oct 2013 (actual). Primary completion is estimated for Dec 2026, 158 months after the start.
Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 158 months is above that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →